InterMune to Release Third Quarter Financial Results on November 5

BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq:
ITMN) announced today that it will release third quarter 2009 financial
results on Thursday, November 5, 2009 at 4:00 p.m. Eastern time. A live
conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern
time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372
(international), conference ID# 37626791. To access the webcast, please log
on to the company's website at www.intermune.com at least 15 minutes prior to
the start of the call to ensure adequate time for any software downloads that
may be required.

A replay of the webcast and teleconference will be available approximately
three hours after the call. The teleconference replay will be available for
10 business days following the call and can be accessed by dialing
800-642-1687 (U.S.) or 706-645-9291 (international), and entering the
conference ID# 37626791.

About InterMune
InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and hepatology.
InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF)
and hepatitis C virus (HCV) infections. The pulmonology portfolio includes
pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has
been completed and the compound is currently in the pre-registration stage.
The company also has a research program focused on a pirfenidone analog named
ITMN-520. The hepatology portfolio includes the HCV protease inhibitor
compound RG7227 (ITMN-191) that entered Phase 2b in August of 2009 and a
second-generation HCV protease inhibitor research program. For additional
information about InterMune and its R&D pipeline, please visit
www.intermune.com.

SOURCE InterMune, Inc.

Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com